Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIRO-AF: Tirzepatide in Obesity and Atrial Fibrillation
NCT06802081Phase 2Recruiting
- Sponsor
- Cleveland Clinic
- Start
- Apr 2025
- Primary completion
- Dec 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Atrial fibrillation (AFib) and obesity comparing Tirzepatide with Placebo (2 arms). Primary endpoint: Atrial Fibrillation burden at 12 months. Started Apr 2025; status: recruiting.
02
Drugs
03
Conditions
Atrial fibrillation (AFib)obesity
Beyond the preview
Go deeper on NCT06802081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06802081.